William Busse, MD, professor, Allergy, Pulmonary and Critical Care Medicine, commented in an article published by MD Magazine on a phase 3 clinical trial that he is leading. 

The BORA trial is investigating the long-term efficacy of benralizumab for treatment of asthma.  

Results indicate that the medication was remained safe and tolerable in asthma patients during an additional year of treatment. 

Dr. Busse explained that - although the findings are significant - longer treatment observations are still needed. 

“Biologics, in general, are providing keen insight into the mechanisms of asthma, which had not been previously available in other studies,” he said.

Resources:

• "Benralizumab Continues to Show Efficacy, Safety in Phase 3 Trial," MD Magazine, September 26, 2018
• Busse WW, et al. 2019. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 7(1):46-59.